 WATERTOWN, Mass.--BUSINESS WIRE--SQZ Biotechnologies NYSE: SQZ, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that the first clinical translation of the companys Tolerizing Antigen Carrier TAC platform in autoimmune diseases will be for celiac disease, a chronic autoimmune disorder that afflicts millions of patients and has no approved drug treatment. The company anticipates an IND filing in the third quarter of 2022. In preclin 